Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, single-arm study of ofatumumab investigating the safety of an accelerated
infusion schedule of ofatumumab in patients who have received at least one prior therapy for
CLL. The primary endpoint is to evaluate the number of subjects able to complete infusion
number 3 (2000 mg) within 15 minutes of the planned time.